Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022413 | 0.90 | GRM2 (0.55) | GRM2PIK3CGGRIN2BCHRM5PRMT6 | |
| SCHEMBL2025275 | 0.89 | GRM2 (0.54) | GRM2PIK3CGGRIN2BCHRM5PRMT6 | |
| SCHEMBL2025283 | 0.89 | GRM2 (0.54) | GRM2PIK3CGGRIN2BCHRM5PRMT6 | |
| SCHEMBL8270193 | 0.88 | GRM2 (0.57) | GRM2PIK3CGCHRM5HTR2CCYP11B1 | |
| SCHEMBL2027849 | 0.87 | GRM2 (0.60) | GRM2PIK3CGGRIN2BCHRM5ALDH1A1 | |
| SCHEMBL1002074 | 0.87 | GRM2 (0.58) | GRM2PIK3CGPRMT6ALDH1A1SSTR5 | |
| SCHEMBL1003029 | 0.86 | GRM2 (0.52) | GRM2PIK3CGGRIN2BCHRM5PRMT6 | |
| SCHEMBL2021840 | 0.86 | GRM2 (0.43) | GRM2PIK3CGCYP11B2 | |
| SCHEMBL2024338 | 0.85 | GRM2 (0.59) | GRM2PIK3CGPRMT6ALDH1A1CYP11B2 | |
| SCHEMBL12641830 | 0.85 | GRM2 (0.59) | GRM2GRIN2BCHRM5ALDH1A1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885PIK3CG 1735/4885GRIN2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.